Impaired bioenergetics and oxidative damage in the mitochondria are implicated in the etiology of temporal lobe epilepsy, and hyperacetylation of mitochondrial proteins has recently emerged as a critical negative regulator of mitochondrial functions. However, the roles of mitochondrial acetylation and activity of the primary mitochondrial deacetylase, SIRT3, have not been explored in acquired epilepsy. We investigated changes in mitochondrial acetylation and SIRT3 activity in the development of chronic epilepsy in the kainic acid rat model of TLE. Hippocampal measurements were made at 48 h, 1 week and 12 weeks corresponding to the acute, latent and chronic stages of epileptogenesis. Assessment of hippocampal bioenergetics demonstrated a ≥ 27% decrease in the ATP/ADP ratio at all phases of epileptogenesis (p < 0.05), whereas cellular NAD+ levels were decreased by ≥ 41% in the acute and latent time points (p < 0.05), but not in chronically epileptic rats. In spontaneously epileptic rats, we found decreased protein expression of SIRT3 and a 60% increase in global mitochondrial acetylation, as well as enhanced acetylation of the known SIRT3 substrates MnSOD, Ndufa9 of Complex I and IDH2 (all p < 0.05), suggesting SIRT3 dysfunction in chronic epilepsy. Mass spectrometry-based acetylomics investigation of hippocampal mitochondria demonstrated a 79% increase in unique acetylated proteins from rats in the chronic phase vs. controls. Pathway analysis identified numerous mitochondrial bioenergetic pathways affected by mitochondrial acetylation. These results suggest SIRT3 dysfunction and aberrant protein acetylation may contribute to mitochondrial dysfunction in chronic epilepsy.
Introduction
Epilepsy is one of the most common neurological disorders with a lifetime occurrence of about 3% in the general population [23] . Temporal lobe epilepsy (TLE), the most common acquired epilepsy, is typically preceded by an inciting injury resulting in the transformation of a normal brain circuit to a hyperexcitable one by a process known as epileptogenesis. Metabolic and bioenergetic dysfunction, particularly in the mitochondria, is known to occur with the initial injury and subsequent epileptogenesis, and may contribute to the development of spontaneous seizures [37, 57] .
Impairments in mitochondrial function, such as decreased activities of TCA cycle and electron transport chain (ETC) enzymes, have been found in hippocampi of epileptic patients [39, 75] , and we recently demonstrated reductions in the mitochondrial respiratory and reserve capacities and inhibition of Complex I of the electron transport chain (ETC) in our rat kainic acid (KA) model of chemoconvulsant-induced epilepsy [56, 58] . Biomarkers of oxidative damage have been found in brain and plasma from patients with epilepsy [51, 66] , and our lab has demonstrated increased steady-state levels of mitochondrial ROS [30, 40] and markers of ROS-mediated damage [42, 58, 59] in rodent hippocampi in our rat KA model. However, an underlying mechanism mediating these mitochondrial alterations in bioenergetics and ROS production with epilepsy are unknown.
Acetylation of lysine residues of proteins has recently emerged as a highly conserved post-translational modification (PTM) that regulates the activities of numerous metabolic enzymes within the mitochondria, and therefore may control bioenergetic homeostasis in this organelle [16, 84] . Mitochondrial acetylation is generally considered an inhibitory PTM and acetylation of specific lysine(s) is known to reduce activities of multiple enzymes in the ETC, TCA cycle, fatty acid oxidation (FAO), and ketogenesis, as well as those involved in antioxidant defenses [1, 21, 24, 54, 62, 63, 77, 87] . Accordingly, elevations in mitochondrial acetylation have been found in a variety of tissues in diverse disease states associated with mitochondrial dysfunction [53, 60, 73, 79, 88] . Unlike in the nucleus where acetylation of histones is regulated by the opposing activities of lysine deacetylases (KDACs) and lysine acetyltransferases, mitochondrial acetylation is thought to occur non-enzymatically [78] and therefore, may reflect activities of mitochondrial deacetylases [50, 76] .
The sirtuins are a highly conserved protein family of Class III KDACs implicated in the maintenance of cellular homeostasis through regulation of energy metabolism and antioxidant defenses [26] . SIRT1-7 are nicotinamide adenine dinucleotide (NAD+)-dependent lysine deacylases and are located throughout varied cellular compartments [22, 26, 9] . Changes in NAD+ levels have been shown to regulate sirtuin activity, possibly via altered expression and activity of the rate-limiting NAD+ biosynthetic enzyme Nampt [27, 28] . SIRT1 is a nuclear-cytosolic deacylase known to control the activity of numerous enzymes and transcription factors in these cellular compartments [6, 22] . Mitochondrial SIRT3 has been shown to control global levels of mitochondrial acetylation and is also thought to regulate mitochondrial energy metabolism and antioxidant activities by direct deacetylation of substrate enzymes in these pathways [36, 48] . Many neuroprotective effects of SIRT3 have been found [2] , and it was recently shown that overexpression of SIRT3 in vitro reduces neuronal death in response to excitotoxic cell death [35] . The role of SIRT3 in epilepsy has not yet been explored, although our laboratory has recently implicated reduced activities of manganese superoxide dismutase (MnSOD) and Complex I, two known SIRT3 substrates, during epileptogenesis [43, 58] . This suggests that SIRT3 dysfunction and the resulting increase in mitochondrial acetylation may underlie the deficits in mitochondrial function and inhibition of bioenergetic enzymes known to occur with the development of chronic epilepsy.
In the present study, we hypothesized that impairments in hippocampal bioenergetics are associated with reductions in SIRT3 activity and consequent increases in mitochondrial acetylation during epileptogenesis in the rat KA TLE model. Further, we sought to determine if aberrant acetylation of SIRT3 bioenergetic and metabolic substrates are associated with spontaneous seizure activity. We also aimed to characterize levels of mitochondrial protein acetylation in hippocampi of rats with chronic epilepsy in our KA chemoconvulsant model of epilepsy using an innovative, mass spectrometry-based acetylomics approach. Additionally, we aimed to delineate affected mitochondrial biological processes by analyzing the resulting profile of acetylated proteins via gene ontology and pathway analysis.
Methods

Kainic acid-induced epileptogenesis
Animal studies were carried out in accordance to the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 80-23, revised 1996) . All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Colorado, Anschutz Medical Campus. Adult, male Sprague Dawley rats (~300-350 g) received a subcutaneous injection of saline or K (11 mg/kg; dissolved in sterile saline, pH 7.4; AG Scientific, Inc. #K-1013) to induce status epilepticus (SE), a period of constant seizure activity known to incite brain injury in chronic epilepsy models. Rats were anesthetized using carbon dioxide and immediately euthanized by decapitation at 48 h, 1 week and 12 weeks after KA administration to encompass the acute, latent and chronic periods of epileptogenesis. Hippocampi were dissected and immediately frozen in liquid nitrogen or crude mitochondria were isolated from hippocampal tissues [42] . All tissues were stored at − 80°C.
Monitoring of convulsive seizures
Rats were observed for acute seizure activity during SE and behavioral seizures were scored using a modified Racine scale [40] with only Class III, IV and V motor seizures considered. Briefly, motor seizures were scored on the following scale: Class III -unilateral forelimb clonus, Class IV -bilateral forelimb clonus with rearing, and Class Vbilateral forelimb clonus with rearing, falling, and/or hind limb clonus. SE was defined as at least five Class III or higher seizures followed by a period of continuous seizure activity. Animals that received an injection of KA but did not progress into SE were deemed "non-responders". To confirm the development of spontaneous seizures in the chronic time point, rats were monitored with 24 h video recording for 72 h in the University of Colorado In Vivo Neurophysiology Core for seizure number, duration and severity at the end of the 12 week time point. Rats observed to have spontaneous, behavioral seizures during the video monitoring period were considered chronically epileptic.
Mitochondrial and cytosol isolations
Crude hippocampal mitochondria were isolated according to our previously published methodology [42] . Briefly, hippocampal homogenates were centrifuged at 800 g at 4°C for 10 min and the resulting supernatant was then centrifuged at 16,000 g at 4°C for 10 min. Following the second centrifugation step, the supernatant was isolated as the cytosolic fraction and the pellet was resuspended to obtain the mitochondrial fraction. One hippocampus was used for western blot analyses from mitochondrial and cytosolic fractions and the mitochondrial acetyl-protein immunoprecipitations. For mass spectrometry-based mitochondrial acetyl-lysine immunoprecipitations, both hippocampi were used for mitochondrial isolations.
Western blot analysis
Hippocampal mitochondrial and cytosolic fractions were prepared as described above and used for protein expression analysis. Protein expression of SIRT3 (Cell Signaling 5490), NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 9 (Ndufa9) (Abcam ab14713), acetyl-isocitrate dehydrogenase 2 (ac-IDH2) (Gene Tel #AC0004), SIRT1 (Millipore 08-131), Nampt (Bethyl A300-372A), and acetylMnSOD K122 (ac-MnSOD) [68] were determined via standard Western blot techniques, quantified with Image J software (NIH) or Image Lab 5.1 (Bio-Rad) and normalized to GAPDH (Cell Signaling 2118) or β-actin (Sigma) for cytosolic loading controls, VDAC (Abcam ab15895) for mitochondrial loading control, or total protein load for gels run using TGX Stain-free gels (Bio-Rad) [10, 72] .
HPLC analysis of ATP and ADP
ATP and ADP were measured in hippocampi according to previously published methods [5, 61] . The tissues were quickly dissected, frozen with liquid nitrogen and tissue weight obtained. Hippocampi were sonicated in 10% w/v 0.42 N perchloric acid, centrifuged at 16,000 g at 4°C for 15 min 200 μL of the supernatant was neutralized with 20 μL 4 N KOH, and left at − 20°C for at least 10 min. The neutralized supernatant was centrifuged at 16,000 g at 4°C for 15 min to ensure removal of perchlorate, and 100 μL of this supernatant was mixed with 100 μL 100 mM K2HPO4, pH 7.0. A 20 μL aliquot of this mixture was injected onto the HPLC system. ATP and ADP were analyzed using a HPLC equipped with a spectrophotometric detector (Elite LaChrom System; Hitachi, Japan) set at 258 nm and a YMC-Pack ODS-A column (4.6 × 150 mm, 3 µm, 120 Å; Waters, Milford, MA, USA). The mobile phase was composed of 100 mM K2HPO4, 12% ACN, 4 mM tetrabutylammonium bisulfate and adjusted to pH 5.0 with 4 N KOH and the flow rate was set at 0.8 ml/min. The retention time of ADP was 5.78 min and that of ATP was 7.82 min.
HPLC analysis of NAD+
NAD+ was measured in hippocampi according to previously published methods [5, 55, 61] . The tissues were quickly dissected, frozen with liquid nitrogen and tissue weight obtained. Hippocampi were sonicated in 10% w/v 0.42 N perchloric acid, centrifuged at 16,000 g at 4°C for 15 min 200 μL of the supernatant was neutralized with 20 μL 4 N KOH, and left at − 20°C for at least 10 min. The neutralized supernatant was centrifuged at 16,000 g at 4°C for 10 min, and 160 μL of this supernatant was mixed with 40 μL 100 mM K2HPO4, pH 7.0. A 20 μL aliquot of this mixture was injected onto the HPLC system. NAD + was analyzed using a HPLC equipped with a spectrophotometric detector (Elite LaChrom System; Hitachi, Japan) set at 261 nm and a 3 μM, 15 cm x 4.6 cm SUPELCOSIL™ LC-18-T HPLC column (Sigma Aldrich). The mobile phase was composed of 100 mM K2HPO4, 5% methanol and adjusted to pH 5.0 with 4 N KOH and the flow rate was set at 0.8 ml/min. The retention time of NAD+ at 25.50 min.
Hippocampal mitochondrial acetyl-lysine immunoprecipitation and protein expression
300 μg of hippocampal mitochondrial lysates were incubated with acetyl-lysine primary antibodies (Cell Signaling #9814 and #9441) overnight following 1 h pre-clearing with Protein A/G beads (Santa Cruz sc-2003) at 4°C. Protein A/G beads were then added to the supernatant and lysates were rotated overnight at 4°C. Beads were washed with PBS-T and eluted with Laemmli Buffer at 100°C. Expression of global mitochondrial acetylated proteins (Abcam ab22550) and acetyl-Ndufa9 (ac-Ndufa9; Abcam ab14713) were determined via standard Western blot techniques and quantified with Image J software (NIH).
Acetylomics analysis
Acetylomic analysis of mitochondrial proteins was performed according to the protocol provided by Cell Signaling Technology [67] . Acetylated BSA was used as an internal standard for quality control. Briefly, mitochondrial proteins (2 mg) were trypsinized and enriched utilizing a mixture of monoclonal acetyl-Lys antibodies conjugated to beads (Cell Signaling #13416). Purified acetyl-peptide analysis was performed using nano-UPLC-MS/MS (Bruker Daltonics, Inc., Billerica, MA) at a flow rate of 800 nL/min with a gradient of 5-50% 0.1% formic acid in acetonitrile (ACN) over 60 min on C18 trapping (20 × 0.1 mm 2 ) and analytical columns (150 × 0.10 mm 2 ). The nano-UPLC was coupled to a nano-ESI source and Impact HD Q-TOF mass spectrometer (Bruker Daltonics, Inc., Billerica, MA). The instrument was operated using intensity dependent CID MS/MS. MS/MS data analysis was performed using Mascot (version 2.2.04, Matrixscience) by Proteinscape (Bruker Daltonics, Inc., Billerica, MA). Peptides were searched in Mascot using SwissProt 2016_05, allowing up to 4 missed tryptic cleavages with variable carbamidomethyl (C), deamidated (NQ), oxidation (M), and acetyl (K) modifications. Peptides with a minimum ion score of 20 were accepted. The final protein list included only protein IDs with a probability of 99% or greater and peptide IDs required a 95% cutoff. The resulting gene list of acetylated proteins was analyzed by the Gene Ontology (GO) Consortium web toolkit to determine pathway enrichment by entering the protein accession list into the GO PANTHER website [3, 18] . Analysis for gene ontology used the Bonferroni correction for multiple testing with statistical significance determined by p < 0.05.
Statistical analyses
Results are presented as means ± SEM. For all biochemical analyses, GraphPad Prism 6.0 was used to perform Student's t-test or oneway ANOVA analysis. Tukey's multiple comparisons post-hoc tests were used where appropriate. Significance was determined using P < 0.05.
Results
Hippocampal bioenergetics are impaired the KA model of epilepsy
We have previously shown mitochondrial respiratory deficits and alterations in the glycolytic capacity in the rat KA TLE model [56] . Since this suggests impairment in bioenergetics, we measured the ratio of ATP/ADP at three time points 48 h, 1 week and 12 weeks after KA treatment, which correlate with the acute, latent and chronic periods of epilepsy development. The ATP/ADP ratio was decreased in the hippocampus of KA-treated rats versus controls by 28% in the acute, 35% during the latent, and by 27% in the chronic phase of KA-induced epilepsy (all p < 0.05; Fig. 1A ), indicating a deficit in cellular bioenergetics. Previous work from our laboratory has also shown alterations in the cellular and mitochondrial redox state, as indicated by decreases in the ratios of reduced to oxidized glutathione (GSH/GSSG) and Coenzyme A (CoASH/CoASSG), respectively, during epileptogenesis in the rat KA TLE model [59] . The cellular and mitochondrial redox states are strongly influenced by the NAD+/NADH ratios in these compartments, as is the production of ATP as these metabolic co-factors are utilized during energy production in glycolysis, the TCA cycle and during oxidative phosphorylation [77] . Measurement of NAD+ in the hippocampus revealed decreases of 41% and 42% at the acute and latent time points, respectively (both p < 0.05), but no change in spontaneously epileptic rats in the chronic time point relative to controls (Fig. 1B ). These data demonstrate impairment of hippocampal bioenergetics and NAD+ levels in the KA rat TLE model.
Enzymes regulating bioenergetics
We next investigated the role of SIRT3 in these bioenergetics deficits and previously observed indices of mitochondrial dysfunction and oxidative stress in this model [30, 40, 42, 56, 58, 59 ] by measuring its protein expression and acetylation status of select substrates. Protein expression of SIRT3 was unchanged at the acute time point following KA-induced SE (p > 0.05), modestly elevated by 14% during the latent period and decreased by 14% in the chronic time point (both p < 0.05; Fig. 2A ). As SIRT3 regulates levels of mitochondrial acetylation, and increases in mitochondrial acetylation are associated with decreases in SIRT3 activity, global mitochondrial acetylation was assessed as a marker of SIRT3 activity. Hippocampal mitochondrial acetylation was unchanged during the acute and latent time points, but was elevated by 60% in spontaneously epileptic rats, indicating a reduction in SIRT3 activity in chronic epilepsy (Fig. 2B) .
Given the changes in SIRT3 activity and NAD+ levels, we then assessed levels of Nampt, the rate-limiting enzyme in the production of NAD+. Hippocampal protein expression of Nampt was decreased by 26% and 30% versus controls at the acute and chronic time points, respectively (both p < 0.05), but not in the latent period (p > 0.05; Fig. 3A ). Protein levels of SIRT1, a nuclear-cytosolic deacetylase implicated in mitochondrial function through deacetylation of transcription factors regulating mitochondrial biogenesis and function, were also assessed. SIRT1 expression was unchanged at all time points in KAtreated versus control animals (all p > 0.05; Fig. 3B ), prompting us to focus our investigation into a mechanism mediating the impairments in mitochondrial function and bioenergetics during epileptogenesis on the role of SIRT3 and aberrant mitochondrial acetylation. Similarly, since we primarily found changes during the chronic time point, we decided to focus the remaining efforts on this phase of epilepsy.
Increased acetylation of SIRT3 metabolic substrates
Since SIRT3 is known to regulate levels of mitochondrial ROS, ATP production and the mitochondrial redox state, we investigated changes in the acetylation state of SIRT3 substrates known to regulate these biological processes. SIRT3 has been shown to deacetylate, and therefore regulate the activity of, the mitochondrial antioxidant MnSOD to control levels of mitochondrial ROS [68] . We have previously shown that partial deficiency of MnSOD lowers seizure threshold and complete deficiency causes epilepsy [41, 43] , raising the possibility that a decrease in MnSOD activity secondary to decreased SIRT3 activity may be associated with epileptogenesis. Indeed, acetylation of lysine 122 (K122) of MnSOD, a known SIRT3 target, was increased by 20% in spontaneously epileptic rats versus controls (p < 0.05; Fig. 4A) .
We have previously shown decreased activity of Complex I of the ETC at the acute and chronic time points in the KA model [58] , which may reduce ATP production through this mitochondrial pathway. SIRT3 has been shown to deacetylate the Ndufa9 subunit of Complex I, Fig. 3 . Decreased Nampt protein expression during acute and chronic phases and no change in SIRT1 protein expression at all time points of epileptogenesis in hippocampus. Hippocampal nuclear-cytoplasmic (A) Nampt and (B) SIRT1 protein expression during epileptogenesis. Nampt expression normalized to total protein load for both Control and Kainic acid (KA)-treated at all time points. SIRT1 expression normalized to same loading control for both Control and KA-treated at each time point (acute: GAPDH, latent: GAPDH, chronic: actin). Data are normalized to Control mean value. Representative blot images below. Values are mean ± SEM (n = 3-14 per group). * , p < 0.05 vs Control. resulting in enhanced Complex I enzymatic activity and increases in ATP production [1] . As our current data demonstrated an impaired ATP/ADP ratio, we assessed acetylation of Ndufa9 and found an 81% increase in the acetyl-Ndufa9/Ndufa9 ratio versus controls (p < 0.05; Fig. 4B ).
Previous studies from our laboratory have also shown impairments in the mitochondrial redox state, as demonstrated by a decrease in the CoASH/CoASSG ratio, indicating a more oxidized mitochondrial environment, during epileptogenesis [59] . SIRT3 has been shown to regulate the mitochondrial redox state by enhancing activity of the TCA cycle enzyme, IDH2, through deacetylation of lysine 413 (K413) [63, 87] . IDH2 converts isocitrate to α-ketoglutarate in a reaction that converts NADP+ to NADPH, which can result in a more reduced mitochondrial redox state due to the subsequent regeneration of GSH and CoASH from NADPH [31, 63] . Therefore, we measured the acetylation state of IDH2 and found a 119% increase in acetyl-IDH2 K122 in spontaneously epileptic rats versus control animals (p < 0.05; Fig. 4C ).
Acetylomics analysis of mitochondrial protein
In order to follow up on the acetylation of specific protein targets described above, we applied an acetylomics approach to examine overall changes in mitochondrial protein acetylation in the chronic phase of epilepsy in this KA rat TLE model (Fig. 5) . Here, we identified a total of 333 proteins from our enriched mitochondrial fractions from rat hippocampus, with an overlap of 227 proteins from both KA-treated and control animals. Of these mitochondrial proteins, 38 were unique to control samples alone, whereas 68 were identified only in hippocampal mitochondria from chronically epileptic rats (Supplemental File 1).
These results represent an approximate 79% increase in unique acetylated proteins found in spontaneously epileptic rats versus controls. Additionally, we identified 489 and 543 acetyl-peptides in control and chronic samples, respectively, compared to 1178 and 1270 total peptides found. Our acetylomics approach provided an approximate 42% enrichment of acetyl peptides (Supplemental File 2) .
The resulting protein lists were examined for biological pathway enrichment using the Gene Ontology Consortium toolkit. This search identified numerous mitochondrial pathways with significant enrichment; including, isocitrate metabolic processes, TCA cycle, energy coupled proton transport, NADH metabolic processes, aerobic respiration, ATP biosynthesis, and succinate metabolic processes, among many others (Supplemental File 3). These results confirm previously reported pathways impacted via protein lysine acetylation within the mitochondria and support a potential mechanism for acetylation-induced mitochondrial dysregulation.
Discussion
The key novel findings from the present study are that SIRT3 expression is reduced and global mitochondrial acetylation is increased, suggesting SIRT3 activity is impaired, in the hippocampus of chronically epileptic rats and this is associated with impaired bioenergetics and a decrease in protein expression of Nampt, the rate-limiting enzyme in NAD+ biosynthesis. Moreover, rats with chronic spontaneous seizures also demonstrate increased acetylation of several SIRT3 bioenergetic and metabolic substrates, including the mitochondrial antioxidant MnSOD, Ndufa9 of ETC Complex I and the TCA cycle enzyme IDH2. Mass spectrometry-based acetylomics data revealed a greater abundance of acetylated proteins and peptides in hippocampal mitochondria from chronically epileptic rats versus controls and identified multiple mitochondrial pathways affected by protein lysine acetylation. To our knowledge, this is the first study to show a reduction in the expression of SIRT3 and increased acetylation of mitochondrial enzymes with chronic epilepsy. Further, our current results also provide the first mass spectrometry acetylomics data in rat hippocampal mitochondria. Together, these results suggest a potential role for aberrant mitochondrial function due to protein acetylation via SIRT3 in chronic acquired epilepsy.
Impaired bioenergetics during epileptogenesis in rat TLE model
Our data demonstrate that epileptogenic injury impairs hippocampal bioenergetics, as assessed by a decrease in the ATP/ADP ratio. 
L.B. Gano et al. Free Radical Biology and Medicine 123 (2018) 116-124
The decrease in the acute and latent time points could reflect the large metabolic demand of seizure activity following SE, which is known to deplete energy reserves and decrease cellular ATP levels [38, 83] . We have also shown a decrease in the maximal respiratory and reserve capacities in hippocampal synaptosomes in the acute and chronic time points in rat TLE models [56] , which could reflect a decline in the ability to produce ATP on demand during these phases of epilepsy development. Hence, the decrease in the ATP/ADP ratio during the acute and latent time points could reflect an increase in the utilization of ATP to maintain synaptic activity following SE, while the continued impairment during the chronic phase could be due to an inability to produce ATP, possibly as a result of mitochondrial dysfunction. To our knowledge, this is the first study to show a decrease in NAD + levels in the hippocampus of rats following epileptogenic injury. Previous studies have shown changes in NAD(P)H fluorescence in epileptic patients and rats, indicating an alteration in the total NADPH and NADH pools [32] , as well as an increase in the NADH/NAD+ ratio, as assessed by the lactate dehydrogenase ratio, following seizure activity in rats [17] . Further, others have shown a decrease in NAD+ levels in vitro following excitotoxic injury [45, 46] . We detected an early decline in hippocampal NAD+ levels at 24 h (data not shown) and 48 h after KA-induced SE, which is similar to decreases in brain NAD+ found shortly after injury in rodent models of cerebral ischemia, axon degeneration and retinal degeneration, which are all associated with SIRT3 dysfunction [13, 19, 44, 49, 85] .
Technical limitations currently prevent us from accurately measuring the mitochondrial pool of NAD+, so it is possible that the lack of change found in total NAD+ levels in the chronic period reflects maintenance of cytoplasmic NAD+ levels, which would sustain glycolysis to produce ATP. This is possible, as we have shown no change in the glycolytic rate during the chronic time point of epileptogenesis [56] . However, our finding of increased mitochondrial protein acetylation during the chronic time point is reflective of a decrease in mitochondrial NAD+ levels, as manipulation of the activity of Complex I of the ETC to decrease the mitochondrial NAD+/NADH ratio can increase mitochondrial acetylation, whereas supplementation of the NAD + precursor nicotinamide mononucleotide to boost NAD+ levels has been shown to reduce global levels of mitochondrial acetylation [33] .
Reduced SIRT3 activity and Nampt expression and increased mitochondrial acetylation
Our observation of an increase in SIRT3 expression in the latent time point following KA-induced SE, but a decrease during the chronic period, is similar to in vitro findings from others. It was recently shown that low dose of administration of glutamate and the glutamate receptor agonists NMDA and KA increased SIRT3 protein expression in mouse primary cortical neurons, however high dose exposure decreased SIRT3 expression [11] . This may suggest an initial compensatory increase in SIRT3 expression to maintain mitochondrial function upon glutamate receptor activation following seizure activity, as has also been shown acutely in vitro in mouse primary cortical neurons with NMDA administration [35] .
The increase in mitochondrial acetylation during the chronic time point suggests decreased activity of SIRT3. SIRT3 has been shown to be the major mitochondrial deacetylase as knockout of SIRT3, but not deficiency of mitochondrial SIRT4 or SIRT5, increases mitochondrial acetylation levels in mice [48] . This decline in SIRT3 activity is also consistent with the known impairments in mitochondrial function found in chronic epilepsy [39, 56, 57, 75] , as SIRT3 has been shown to positively regulate mitochondrial function by enhancing the activity of multiple enzymes in all energy producing pathways in the mitochondria via direct deacetylation [1, 24, 26, 63, 87] . Similarly, a loss of SIRT3 activity could also contribute to the decrease in the ATP/ADP ratio found in chronically epileptic rats, which is supported by a recent study demonstrating decreased ATP levels in the cerebral cortex and hippocampus of mice deficient in SIRT3 [11] . Decreases in SIRT3 activity and consequent increases in mitochondrial acetylation have been shown in other pathological states known to involve mitochondrial dysfunction and metabolic impairments [25, 60, 79, 88] . However, to our knowledge this is the first study to demonstrate dysregulation of SIRT3 and associated increases in mitochondrial acetylation in chronic epilepsy.
The reduction in Nampt protein expression during the acute and chronic time points may contribute to the decrease in NAD+ levels we found during the acute and latent time points, as well as the bioenergetics impairments during these phases of epilepsy. As the rate-limiting enzyme in the NAD+ salvage pathway, Nampt converts nicotinamide to nicotinamide mononucleotide, which is then further converted to NAD+ by nicotinamide mononucleotide adenylyl transferase (NMNAT) 1-3, which reside in different cellular compartments [29, 74] . This salvage pathway is the primary method to regenerate NAD+ from the nicotinamide produced as a byproduct of the activities of NAD+-consuming enzymes, such as the sirtuins [74] . It is possible that a reduction in the level of this important NAD+ biosynthetic enzyme could also lead to an increase in cellular levels of nicotinamide, which has also been shown to inhibit sirtuin activity [74] . Further, Nampt inhibition has been shown to enhance neuronal injury in postischemic stroke [81] and methods to increase Nampt activity are neuroprotective Fig. 5 . Mitochondrial acetylomics analysis in a model of KA induced epileptogenesis. Enriched mitochondrial samples were subjected to acetyl-immunopurification followed by nHPLC-MS/MS analysis. A significant number of unique features were identified in the KA samples. In total, 333 proteins were identified and include 227 which overlap between the samples, whereas 38 were unique to control samples alone and 68 were unique to KA treatment. This analysis identified 490 and 543 acetyl peptides in control and KA samples out of 1179 and 1270 total peptides, respectively. [14, 69, 80, 86, 89] . Reduced expression of hippocampal Nampt protein has been found with aging, concurrent with decreases in NAD + [47, 64] , but to our knowledge this is the first study to show changes in Nampt protein levels in epilepsy.
We did not find a change in the expression of the nuclear-cytoplasmic deacetylase SIRT1. Two recent studies have assessed SIRT1 in the acute time point following SE in rats. In the pilocarpine rat model of TLE, SIRT1 protein expression and activity were shown to increase in the hippocampus acutely following SE [82] . Interestingly, another study found no change in total cellular or cytoplasmic SIRT1 protein in rat following KA-induced SE, but demonstrated a large increase in nuclear levels of SIRT1 protein during this acute time point [7] . However, neither of these studies examined SIRT1 in the chronic time point of epileptogenesis.
Increased acetylation of SIRT3 metabolic and antioxidant substrates
Overall, our analysis of rat hippocampal mitochondrial fractions in this model provides an in-depth look at potential mechanistic acetylation targets. Additionally, these results confirm previous analyses in whole brain fractions, which demonstrate a preponderance of protein acetylation among mitochondrial metabolic and antioxidant pathways [15] . The increased acetylation state of the known SIRT3 substrates MnSOD, Ndufa9 of ETC Complex I, and IDH2 in spontaneously epileptic rats further demonstrates a decrease in SIRT3 activity in the chronic phase. As increases in lysine acetylation of these proteins have been shown to impair enzymatic activity [1, 63, 68, 87] , these changes are not only reflective of reduced SIRT3 activity, but may also contribute to the metabolic dysfunction and impaired redox state known to occur during epileptogenesis.
An increase in acetylation of MnSOD on K122 has been shown to impair enzymatic activity and increase mitochondrial levels of ROS [4, 68] . Several lines of evidence implicate elevated levels of mitochondrial ROS with epilepsy. In studies with mice partially and completely deficient for MnSOD, Sod2
+/-and Sod2 -/-mice, we have previously shown that loss in the activity of this critical mitochondrial antioxidant increases markers of mitochondrial ROS and results in spontaneous seizure activity [41, 43] . The increase in ROS with loss of MnSOD activity was causally implicated in seizure activity as seizure duration and seizure numbers per day were attenuated with administration of a catalytic antioxidant [43] . Further, we have shown that antioxidant administration ameliorates the increased mitochondrial ROS and neuronal death in the KA rat TLE model [40] . More recently, it was demonstrated that a combination of the antioxidant compounds sulforaphane, a Nrf2 inducer, and N-acetyl cysteine decreased epilepsy progression in rats [52] . These results demonstrate an important role for the loss of MnSOD activity and elevated levels of mitochondrial ROS in the development of chronic epilepsy and our current data suggests acetylation of MnSOD could play a role. Enhanced acetylation of the ETC Complex I subunit Ndufa9 has previously been shown to decrease Complex I activity resulting in diminished production of ATP [1] . Importantly, loss of Complex I activity has also been found in hippocampus tissue of epileptic patients [39] . Impaired Complex I activity has also been demonstrated by us in chronically epileptic rats in this same model of KA-induced epilepsy [58] , as well as in Sod2
-/-mice with spontaneous seizures [43] . Thus, increased acetylation of Ndufa9 in chronic epilepsy could result in decreased Complex I activity and ATP production, which is further supported by our current results demonstrating a reduction in the ATP/ ADP ratio. Increased acetylation of the TCA cycle enzyme IDH2 on lysine 413 (K413) has been shown to reduce enzymatic activity, thereby decreasing conversion of the cofactor NADP+ to NADPH, which impairs regeneration of GSH, resulting in a more oxidized cellular environment, [63, 87] . We have previously demonstrated a shift in the redox state towards a more oxidized cellular and mitochondrial environment in the chronic phase of epilepsy in this rat model of TLE [59] . Further, a decrease in levels of GSH in brain tissue from epileptic patients has also been shown [51] . Loss of IDH2 activity has been shown to contribute to mitochondrial dysfunction in Parkinson disease models [34] and mutations in IDH2 are associated with seizures as the initial symptom in patients with low-grade gliomas [65, 90] . Additionally, TCA cycle dysfunction has been documented by our lab and others in animal models of epilepsy [12, 37, 40] . Specifically, we have shown inactivation of the oxidant-sensitive enzyme aconitase [40] , which precedes IDH2 in the TCA cycle, and others have demonstrated a loss in the activity of alphaketoglutarate dehydrogenase [12] , the enzyme following IDH2 in the TCA cycle. Therefore, increased acetylation, and possible subsequent decreased activity, of these TCA cycle enzymes is another possible source of the metabolic dysfunction and redox imbalance found in chronic epilepsy.
Conclusions
Our current results demonstrating increases in mitochondrial protein lysine acetylation in chronic epilepsy suggests an intriguing link to the known deficits in mitochondrial function and the redox dysfunction known to occur during epileptogenesis. Identification of additional enzymes with aberrant hyperacetylation and the associated affected pathways during epileptogenesis may provide further mechanistic insight into the development of spontaneous seizures. Further, activation of SIRT3 during the epileptogenic cascade may attenuate the resulting hyperacetylation of mitochondrial proteins and prevent the associated metabolic dysfunction. Methods to enhance cellular levels of NAD+ are known to activate SIRT3 [33, 44, 70, 8] and compounds found to boost cellular levels of NAD+ have shown efficacy in rodent models of other neurodegenerative diseases such as Alzheimer's disease, Parkinson disease, traumatic brain injury, amyotrophic lateral sclerosis, axon degeneration, diabetic neuropathies and retinal dysfunction [14, 19, 20, 44, 69, 71, 80, 86] . Therefore, methods to increase neuronal NAD+ to activate SIRT3 may be effective therapies to prevent mitochondrial dysfunction during epileptogenesis and attenuate the development of chronic epilepsy.
